B · Normal
On October 25th, Johnson & Johnson reported that its first RIPTAC™ molecule, JNJ-6143, achieved a 75% tumor response rate in the treatment of advanced prostate cancer.
Related telegraphs
[Most of the main domestic futures contracts rose, with methanol and asphalt ris
10-26 11:36
[Apple customer service responds to “iPhone Duo breaks in some channels”: Prices
10-26 10:07
[Ascletis Pharmaceuticals: A new drug clinical trial application for ASC39 oral
10-26 08:21
October 26th: U.S. stock futures weakened at the beginning of Asia-Pacific tradi
10-26 06:00
On October 26th, Musk stated that SpaceX will not acquire any new cloud service
10-26 05:07
On October 26th, Elon Musk said that SpaceX completed US$40 billion in debt fina
10-26 03:41
Comments